Related Experiment Video
Updated: Feb 5, 2026

Quantification of Filamentous Actin F-actin Puncta in Rat Cortical Neurons
Published on: February 10, 2016
Current developments in pharmacotherapy for actinic keratosis
Elena Campione1, Alessandra Ventura1, Laura Diluvio1
1a Dermatology Clinic , University of Rome Tor Vergata , Italy.
Introduction:
Actinic keratosis (AK) is a superficial squamous cell carcinoma (SCC) where chronic sun exposure playing central role in its pathogenesis. UVB causes direct damage to DNA, producing pyrimidine dimers, and suppressing the protective role of p53. The stepwise progression of AK, with increased expression of anti-apoptotic Bcl-2, favors progression to SCC. Moreover, the dermal response characterized by inflammation and mediated by prostaglandins is a critical component of tumorigenesis that promotes tumor growth, tissue invasion, angiogenesis and metastasis. Other risk factors are represented by age, gender, phototype and drugs.
Areas Covered:
In this review, the authors document the recent developments of different therapies used to treat AK and provide their perspectives on current and future treatment strategies.
Expert Opinion:
The usefulness of long-term treatment with piroxicam and sun filters or diclofenac targeting the inflammation phases of skin tumorigenesis favors AK's healing and provides greater control of the cancerization field. Nonsteroidal anti-inflammatory drugs can be safely used in patients who use photosensitizing drugs and, therefore, are more at risk of developing skin tumors. Immunomodulatory therapies, which require shorter treatment, are characterized by more common local side effects, and need more attention by the dermatologist in the concern of patient education, resulting essential to improve adherence and outcomes.
Insights
Actinic keratosis (AK) treatments are evolving. Long-term nonsteroidal anti-inflammatory drugs (NSAIDs) and sun filters manage AK, while immunomodulatory therapies offer shorter treatment with careful patient education for better outcomes.
Area of Science:
- Dermatology
- Oncology
- Photomedicine
Background:
- Actinic keratosis (AK) is a precursor to squamous cell carcinoma (SCC), driven by chronic sun exposure and DNA damage.
- UVB radiation, p53 suppression, and increased Bcl-2 expression contribute to AK progression.
- Inflammation mediated by prostaglandins is crucial for skin tumorigenesis, promoting growth, invasion, and metastasis.
Purpose of the Study:
- To review recent therapeutic developments for actinic keratosis (AK).
- To provide expert perspectives on current and future AK treatment strategies.
Main Methods:
- Review of current literature on AK therapies.
- Analysis of treatment efficacy and side effect profiles.
Main Results:
- Long-term piroxicam/sun filters or diclofenac aid AK healing and control field cancerization.
- NSAIDs are safe for patients using photosensitizing drugs, reducing skin tumor risk.
- Immunomodulatory therapies show shorter treatment durations but higher local side effects, necessitating patient education.
Conclusions:
- Both long-term NSAIDs and shorter-term immunomodulatory therapies are valuable for AK management.
- Patient education is critical for adherence and successful outcomes, especially with immunomodulatory treatments.
- Future strategies may involve personalized approaches combining different therapeutic modalities.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Actin Treadmilling
Introduction to Actin
Actin Polymerization
The nucleation phase involves forming a stable nucleus consisting of three actin monomers to form a new actin filament. Actin-binding proteins such as formins and Arp2/3 complex help filament growth post-nucleation. The Formins form straight...
Electrical Current

